Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Asmuth

Infectious Disease Sacramento, CA Medical Doctor

NPI 1972573046 CMS profile 533426

4150 V Street, Uc Davis Health System Pssb G500, Sacramento, CA 95817

Open in the dashboard

General payments

$316,090

329 records reported · program years 2019–2025

Research payments

$1,513

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$610,006 paid to institutions, not to them · program years 2019–2021

Through program year 2025, David Asmuth of Sacramento, CA is reported in the CMS Open Payments database as having received $316,090 across 329 general payments and $1,513 in research payments paid to them. Separately, studies naming them as principal investigator received $610,006 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,182 6
2024 General $6,048 3
2023 General $24,313 12
2022 General $32,760 22
2021 General $52,636 28
2020 General $46,188 49
2019 General $144,962 209
2019 Research $1,513 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Asmuth
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to David Asmuth were reported at $9,182. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year David Asmuth Infectious Disease median Middle half National median
2019 $144,962 $190 $60–$862 $163
2020 $46,188 $124 $32–$606 $114
2021 $52,636 $148 $38–$905 $132
2022 $32,760 $166 $50–$834 $149
2023 $24,313 $171 $57–$787 $160
2024 $6,048 $176 $52–$752 $164
2025 $9,182 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ViiV Healthcare Company $152,389 135 payments
  2. Merck Sharp & Dohme Corporation $54,500 75 payments
  3. Napo Pharmaceuticals Inc $53,325 18 payments
  4. Gilead Sciences, Inc. $44,398 73 payments
  5. Janssen Products, LP $10,567 19 payments
  6. Theratechnologies Inc. $884 4 payments
  7. Janssen Biotech, Inc. $23 4 payments
  8. Janssen Scientific Affairs, LLC $4 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $200,228 85 payments
  2. Consulting Fee $85,305 25 payments
  3. Travel and Lodging $23,083 101 payments
  4. Food and Beverage $6,693 116 payments
  5. Honoraria $750 1 payment
  6. Education $31 1 payment
Products named General payments · program years 2019–2025
  1. DOVATO $61,188 54 payments
  2. Mytesi $53,325 18 payments
  3. RUKOBIA $41,247 28 payments
  4. DELSTRIGO $34,354 44 payments
  5. SYMTUZA $10,594 24 payments
  6. ISENTRESS $10,171 8 payments
  7. Biktarvy $10,107 10 payments
  8. Descovy $9,655 15 payments
  9. Truvada $9,420 13 payments
  10. PIFELTRO $6,007 6 payments
  11. Other $6,211 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $1,513 14 payments

Records

343 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record